ArticleGut2021

Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic.

Colleen Gc McGregor et al.PubMed ↗Publisher ↗

No numbers read from the abstract.